Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Nexalin Technology, Inc. (NXL : NSDQ)
 
 • Company Description   
Nexalin Technology Inc. designs and develops neurostimulation products for mental health epidemic. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. Nexalin Technology Inc. is based in Houston, Texas.

Number of Employees: 6

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.00 Daily Weekly Monthly
20 Day Moving Average: 70,265 shares
Shares Outstanding: 17.18 (millions)
Market Capitalization: $17.11 (millions)
Beta: 3.70
52 Week High: $4.49
52 Week Low: $0.59
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -18.02% -21.09%
12 Week -41.01% -50.38%
Year To Date -63.91% -66.21%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1776 YORKTOWN SUITE 550
-
Houston,TX 77056
USA
ph: 832-260-0222
fax: -
nxl@crescendo-ir.com http://www.nexalin.com
 
 • General Corporate Information   
Officers
Mark White - Chief Executive Officer and Chief Financial Office
Carolyn Shelton - Senior Vice President of Quality; Clinical and Reg
Alan Kazden - Director
Ben Hu - Director
Leslie Bernhard - Director

Peer Information
Nexalin Technology, Inc. (EVOL)
Nexalin Technology, Inc. (RAMP)
Nexalin Technology, Inc. (LGTY)
Nexalin Technology, Inc. (ALOT)
Nexalin Technology, Inc. (CXT)
Nexalin Technology, Inc. (TGHI)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Technology Services
Sector: Business Services
CUSIP: 65345B201
SIC: 3845
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 17.18
Most Recent Split Date: (:1)
Beta: 3.70
Market Capitalization: $17.11 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 5.71
Price/Cash Flow: -
Price / Sales: 130.61
EPS Growth
vs. Year Ago Period: -7.14%
vs. Previous Quarter: 46.43%
Sales Growth
vs. Year Ago Period: -48.10%
vs. Previous Quarter: 51.85%
ROE
06/30/25 - -
03/31/25 - -277.92
12/31/24 - -247.11
ROA
06/30/25 - -
03/31/25 - -245.37
12/31/24 - -219.24
Current Ratio
06/30/25 - -
03/31/25 - 4.56
12/31/24 - 7.24
Quick Ratio
06/30/25 - -
03/31/25 - 4.25
12/31/24 - 6.92
Operating Margin
06/30/25 - -
03/31/25 - -6,529.01
12/31/24 - -4,500.59
Net Margin
06/30/25 - -
03/31/25 - -6,529.77
12/31/24 - -4,501.18
Pre-Tax Margin
06/30/25 - -
03/31/25 - -6,528.25
12/31/24 - -4,511.59
Book Value
06/30/25 - -
03/31/25 - 0.17
12/31/24 - 0.28
Inventory Turnover
06/30/25 - -
03/31/25 - 0.25
12/31/24 - 0.23
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©